Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07330648 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

Study acronym: CEASE-GAD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
A placebo-controlled superiority design was used to evaluate the efficacy of 40 mg/ day of Crisugabalin capsules in the treatment of GAD.
Trial Details
NCT Number NCT07330648
Lead Sponsor Anhui Medical University
Conditions
(from sponsor)		 Generalized Anxiety Disorder
Related terms Generalized Anxiety Disorder
Enrollment 216 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov